The vitro efficacy of β-lactam and β-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis
International Journal of Antimicrobial Agents, vol.23, no.4, pp.408-411, 2004 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 23 Issue: 4
- Publication Date: 2004
- Doi Number: 10.1016/j.ijantimicag.2003.09.023
- Journal Name: International Journal of Antimicrobial Agents
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.408-411
- Keywords: β-Lactam, β-Lactamases, Clavulanic acid, M. tuberculosis
- Hacettepe University Affiliated: Yes
Abstract
In vitro activity of β-lactam antibiotics and their β-lactamase inhibitor combinations were evaluated for their activity against clinical isolates of Mycobacterium tuberculosis and M. tuberculosis H37Ra. Agar dilution, the BACTEC 460 system and β-lactamase activity tests were used. Results using the BACTEC 460 and enzyme activity tests showed the best β-lactamase inhibitor for M. tuberculosis H37Ra to be clavulanic acid. Cefazolin-clavulanic acid gave the lowest minimal inhibitory concentration (MIC) values using dilution tests and M. tuberculosis H37Ra. β-Lactam antibiotics were combined with clavulanic acid and tested for in vitro activity against 50 selected multidrug-resistant (MDR) and 50 susceptible clinical isolates. Seventy-four percent of the isolates were inhibited by cefazolin-clavulanic acid combination. These results suggested that an appropriate combination of β-lactam and β-lactamase inhibitors might be useful in the treatment of tuberculosis due to multidrug-resistant strains. © 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.